Phathom Q3 2026 slides: profitability milestone, 71% revenue growth

Phathom Pharmaceuticals (PHAT) reported Q3 2026 earnings with $84.7M revenue (71% YoY growth) and $2.1M net cash, slightly missing analyst estimates. The company achieved profitability and strong prescription growth for VOQUEZNA, its lead product. Stock rose 8.03% premarket. Management reaffirmed full-year guidance and expects sustained profitability.

Original reporting
Published Oct 29, 2026, 1:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 1:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PHAT
Bullish
high confidence
Mentioned
$PHAT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHATBullishHigh
01

Why it matters

The earnings beat and profitability milestone suggest near‑term upside, but guidance remains modest and future trial data remain a risk.

02

Market read

Strong earnings beat and cash flow generation provide a fresh catalyst for PHAT, likely prompting short‑term buying interest.

03

What to watch

Upcoming Phase II data and cash‑flow outlook for 2027 could moderate enthusiasm if results disappoint.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Phathom Pharmaceuticals (NASDAQ:PHAT) announced Q3 2026 results, highlighting a 71% YoY revenue increase, operating profit, and cash generation.

Company-level read

Ticker impact

$PHATBullishHigh confidence
Context

Phathom Pharmaceuticals reported Q3 2026 earnings with 71% revenue growth, an EPS beat and a second consecutive quarter of operating profit.

Expected impact

upward pressure as investors price in the earnings beat and cash generation.

Evidence & confidence

The company posted a $0.04 adjusted EPS versus a $0.10 loss estimate and the stock rose 8% pre‑market, indicating strong market reaction.

Market effects

Positive earnings may lift the broader biotech and gastroenterology therapeutic sector.

US biotech investors may see increased risk appetite for similar small‑cap pipelines.

Limited to investors tracking US‑listed biotech stocks.

Counterpoint

If the revenue miss relative to consensus signals demand softness, the rally could be short‑lived.

Key entities

  • Phathom Pharmaceuticals

    US‑listed biotech focused on GERD treatment VOQUEZNA.

  • BlinkRx

    Copay‑assistance partner for VOQUEZNA.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.

$PHATMedAI 8/10

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G